Physician
Hematology
Dr. Pawel J. Muranski, MD
Pawel Muranski works in the field of Hematology. Pawel Muranski has written publications. He has 40 publications published with PubMed. The lastest paper is: 'In the normal repertoire of CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities.'
Publications
- Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia.
- Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.
- Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
- Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.
- The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatme...
- An easy way to make a good anti-tumor chimeric antigen receptor T cell?
- Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.
- Timing and intensity of exposure to Interferon-gamma critically determines the function of monocyte-derived dendritic cells.
- Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells.
- Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells.
- BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.
- Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
- Essentials of Th17 cell commitment and plasticity.
- Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature.
- Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells.
- IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.
- Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
- Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
- Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.
- Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
- Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.
- Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.
- Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
- T helper 17 cells promote cytotoxic T cell activation in tumor immunity.
- Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
- Does IL-17 promote tumor growth?
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.
- Type 17 CD8+ T cells display enhanced antitumor immunity.
- Adoptive immunotherapy of cancer using CD4(+) T cells.
- Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
- Tumor-specific Th17-polarized cells eradicate large established melanoma.
- Toll-like receptors in tumor immunotherapy.
- Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
- Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
- Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients.
- Altered selection of CD4+ T cells by class II MHC bound with dominant and low abundance self-peptides.
- Mature CD4+ T cells perceive a positively selecting class II MHC/peptide complex in the periphery.
- On the role of high- and low-abundance class II MHC-peptide complexes in the thymic positive selection of CD4(+) T cells.
- In the normal repertoire of CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities.
Doctors Specialties
- Hematology
Accepted Insurances
Helpful Reviews
Similar Doctors
|
Dr. Ariel Polish, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Elyse A. Lambiase, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nicholas Campbell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Veerpal Singh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohamed Eldibany, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harry J. Miller, MD |
|
|
Dr. Malvika Varma, MD |
|
|
Dr. Abhilasha Radhakrishnan, MD |
|
|
Dr. Beenu Thakral, MD |